ClinicalTrials.gg
RecruitingNCT05721027Updated Apr 13, 2026

Ibuprofen With or Without Dexamethasone for Acute Radicular Low Back Pain.

A Phase 4 interventional study of Ibuprofen 400 mg and Dexamethasone Oral in Radiculopathy, Lumbosacral Region, Back Pain With Radiation and Low Back Pain, sponsored by Montefiore Medical Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Montefiore Medical Center · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This will be a placebo controlled, randomized, double-blind, comparative effectiveness study, in which we patients are enrolled during an emergency department (ED) visit for acute radicular low back pain (LBP) and followed by telephone two and seven days later. Patients will be randomized to receive an oral dose of dexamethasone for 2 consecutive days or placebo during an ED visit for acute radicular LBP. Every patient will receive a 7 day supply of ibuprofen and a low back pain education session.

02

Conditions studied

  • Radiculopathy, Lumbosacral Region
  • Back Pain With Radiation
  • Low Back Pain

Keywords

  • ibuprofen
  • dexamethasone
  • radiculopathy
  • low back pain
  • back pain with radiation
03

In context

Radiculopathy

483 studies on the registry are indexed under Radiculopathy; 145 are open to participants now.

This study's planned enrollment of 132 is above the median of 60 across 373 interventional studies indexed under Radiculopathy.

Browse Radiculopathy studies →

Lead sponsor

Montefiore Medical Center is the lead sponsor of 416 studies on the registry; 69 are open to participants now.

Of its 87 completed or terminated interventional studies of FDA-regulated products, 76 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present to ED primarily for management of acute radicular LBP, defined as pain or paresthesia originating from the lower back and radiating to the buttock and or leg in a radicular pattern. Some patients may not have prominent LBP but a radicular symptom--we will include these patients as well.
  • Patient is to be discharged home.
  • Age 18-70 Enrollment will be limited to adults \<70 years because of the increased risk of adverse medication effects in older adults.
  • Pain duration \<2 week
  • Prior to the acute attack of radicular LBP, back pain cannot occur more frequently than half of the days in the last 3 months. Patients with more frequent back pain/sciatica are at increased risk of poor pain and functional outcomes.10
  • Non-traumatic cause of pain: no substantial and direct trauma to the back within the previous month
  • Functionally impairing radicular LBP: A baseline score of > 5 on the Roland-Morris Disability Questionnaire

Exclusion criteria

Exclusion Criteria:

  • Not available for follow-up
  • Pregnant
  • Chronic pain syndrome defined as use of any analgesic medication on a daily or near-daily basis
  • Allergic to or intolerant of medications
  • Chronic use
  • to investigational medications: 1) known peptic ulcer disease, chronic dyspepsia, or history of gastrointestinal bleed 2) Severe heart failure ( 2 or worse) 3) Chronic kidney disease ( \<60ml/min) 4) Current use of anti-coagulants 5) cirrhosis ( A or worse) or hepatitis (transaminases 2x the )
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Ibuprofen + dexamethasone + educational intervention

    Ibuprofen 400 mg PO every 8 hours as needed for 7 days + dexamethasone 16 mg PO for day 1 and day 2. Research personnel will provide each participant with a 15-minute educational intervention.

    Drug: Ibuprofen 400 mg · Drug: Dexamethasone Oral · Behavioral: Educational Intervention

  • Placebo comparator
    Ibuprofen + placebo + educational intervention

    Ibuprofen 400 mg PO every 8 hours as needed for 7 days + placebo PO for day 1 and day 2. Research personnel will provide each participant with a 15-minute educational intervention.

    Drug: Ibuprofen 400 mg · Behavioral: Educational Intervention

Interventions

  • Ibuprofen 400 mg PO every 8 hours as needed for 7 days

  • Dexamethasone 16 mg PO during ED visit and next day

  • BehavioralEducational Intervention

    Research personnel will provide each patient with a 15-minute educational intervention. This will be based on National Institute of Arthritis and Musculoskeletal and Skin Diseases Handout on Health: Back Pain information

06

What researchers measure

Primary outcomes

  1. Change in Roland Morris Disability Questionnaire (RMDQ) score

    The change in RMDQ will be evaluated using the 24-item Roland Morris Low Back Pain Disability Questionnaire. The RMDQ is a 24-item patient-reported outcome measure that inquires about pain-related disability resulting from LBP. Items are scored 0 if left blank or 1 if endorsed, for a total RMDQ score ranging from 0 to 24. Higher scores represent higher levels of pain-related disability. The change will be calculated as a difference between the baseline ED visit and the two day follow-up visit (Roland-Morris baseline - Roland-Morris day 2)

    Time frame: 2 days (48 hours)

Secondary outcomes

  1. Worst Radicular LBP

    Worst Radicular LBP pain incurred over the previous 24 hours will be assessed at 2 days and 7 days after ED discharge using a four point ordinal scale: Severe, Moderate, Mild, or None

    Time frame: 2 days and 7 days after ED discharge

  2. Frequency of Radicular LBP

    Frequency of Radicular LBP is evaluated at 2 days and 7 days after ED discharge based on a five point Likert scale: Not at all, Rarely, Sometimes, Usually, and Always

    Time frame: 2 days and 7 days after ED discharge

  3. Analgesic or LBP medication within the previous 24 hours

    Administration of any analgesic or LBP medication (Yes or No) within the previous 24 hours will be assessed at 2 days and 7 days after ED discharge

    Time frame: 2 days and 7 days after ED discharge

  4. Absolute Roland Morris Disability Questionnaire (RMDQ) score

    The Absolute RMDQ score will be tabulated at 2 days and 7 days after ED discharge. The RMDQ is a 24-item patient-reported outcome measure that inquires about pain-related disability resulting from LBP. Items are scored 0 if left blank or 1 if endorsed, for a total RMDQ score ranging from 0 to 24. Higher scores represent higher levels of pain-related disability

    Time frame: 2 days and 7 days after ED discharge

  5. Return to all usual activities

    The patient will be evaluated for the ability to return to all usual activities at 2 days and 7 days after ED discharge based on a binary (Yes/No) response

    Time frame: 2 days and 7 days after ED discharge

  6. Number of visits to any healthcare provider

    The number of aggregate visits to any healthcare provider will be tabulated at 2 days and 7 days after ED discharge

    Time frame: 2 days and 7 days after ED discharge

  7. Satisfaction with Treatment

    Satisfaction with treatment will be evaluated based on a binary (Yes/No) response at 2 days and 7 days after ED discharge

    Time frame: 2 days and 7 days after ED discharge

07

Study locations

2 of 2 sites recruiting
  • Albert Einstein College of Medicine/Montefiore Medical Center - Weiler ED
    The Bronx, New York 10461, United States
    Recruiting
  • Montefiore Medical Center - Moses ED
    The Bronx, New York 10467, United States
    Recruiting
    • Eddie Irizarry, MD · Contact
08

References and documents

Individual participant data

Plan to share: No — No plan to share

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Oct 2027, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2023
First posted
Feb 9, 2023
StartActual
Jul 5, 2023
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05721027
Responsible party
Sponsor
First posted
Feb 9, 2023
Start date
Jul 5, 2023
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Apr 13, 2026

Study contacts

Eddie Irizarry, MD
Contact
eddiriza@montefiore.org
718-920-6626
Eddie Irizarry, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion